Welcome to CDC stacks | Use of Spatial Information to Predict Multidrug Resistance in Tuberculosis Patients, Peru - 23911 | Emerging Infectious Diseases
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Use of Spatial Information to Predict Multidrug Resistance in Tuberculosis Patients, Peru
Filetype[PDF-239.00 KB]


No Related Documents.
You May Also Like:
  1. Multiple Introductions of Multidrug-Resistant Tuberculosis into Households, Lima, Peru
    Personal Author:
    Cohen, Ted; Murray, Megan; Abubakar, Ibrahim; Zhang, Zibiao; Sloutsky, Alexander; Arteaga, Fernando; Chalco, Katiuska; Franke, Molly F.; Becerra, Mercedes C.;
    Published:
    Jun 2011
    Source:
    Emerg Infect Dis. 17(6):969-975.
    Description:
    Two cases of multidrug-resistant tuberculosis (MDR TB) in a household are assumed to reflect within-household transmission. However, in high-incidence areas of MDR TB, secondary cases may arise through exposure to MDR TB in the community. To estimate...
    File Type:
    Filetype[PDF - 189.16 KB]
  2. Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study
    Personal Author:
    Yuen, Courtney M.; Kurbatova, Ekaterina V.; Tupasi, Thelma; Caoili, Janice Campos; Van Der Walt, Martie; Kvasnovsky, Charlotte; Yagui, Martin; Bayona, Jaime; Contreras, Carmen; Leimane, Vaira; Ershova, Julia; Via, Laura E.; Kim, HeeJin; Akksilp, Somsak; Kazennyy, Boris Y.; Volchenkov, Grigory V.; Jou, Ruwen; Kliiman, Kai; Demikhova, Olga V.; Vasilyeva, Irina A.; Dalton, Tracy; Cegielski, J. Peter;
    Published:
    Dec 29 2015
    Source:
    PLoS Med. 12(12).
    Description:
    Background : For treating multidrug-resistant tuberculosis (MDR TB), the World Health Organization (WHO) recommends a regimen of at least four second-line drugs that are likely to be effective as well as pyrazinamide. WHO guidelines indicate only mar...
    File Type:
    Filetype[PDF - 528.88 KB]
  3. National Action Plan for Combating Multidrug-Resistant Tuberculosis : year two report May 2018
    Corporate Author:
    United States. Agency for International Development.. National Institute of Allergy and Infectious Diseases (U.S.). Centers for Disease Control and Prevention (U.S.).
    Published:
    May 2018
    Description:
    NAP-MDR-TB-Year-Two-508.pdf
    File Type:
    Filetype[PDF - 617.78 KB]
  4. Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis
    Personal Author:
    Maryandyshev, Andrey; Pontali, Emanuele; Tiberi, Simon; Akkerman, Onno; Ganatra, Shashank; Sadutshang, Tsetan Dorji; Alffenaar, Jan-Willem; Amale, Rohit; Mullerpattan, Jai; Topgyal, Sonam; Udwadia, Zarir Farokh; Centis, Rosella; D’Ambrosio, Lia; Sotgiu, Giovanni; Migliori, Giovanni Battista;
    Published:
    Oct 17 2017
    Source:
    Emerg Infect Dis. 23(10):1718-1721.
    Description:
    We report the experiences of 5 patients taking bedaquiline with delamanid in combination: 1 patient was cured; 3 culture converted, with 2 continuing and 1 changing therapy; and 1 died from respiratory insufficiency. For 2 patients, QT-interval prolo...
    File Type:
    Filetype[PDF - 997.61 KB]
  5. Scale-up of Multidrug-Resistant Tuberculosis Laboratory Services, Peru
    Personal Author:
    Shin, Sonya S.; Yagui, Martin; Ascencios, Luis; Yale, Gloria; Suarez, Carmen; Quispe, Neyda; Bonilla, Cesar; Blaya, Joaquin; Taylor, Allison; Contreras, Carmen; Cegielski, Peter;
    Published:
    May 2008
    Source:
    Emerg Infect Dis. 14(5):701-708.
    Description:
    Over the past 10 years, the Peruvian National Tuberculosis (TB) Program, the National Reference Laboratory (NRL), Socios en Salud, and US partners have worked to strengthen the national TB laboratory network to support treatment of multidrug-resistan...
    File Type:
    Filetype[PDF - 118.65 KB]